BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 21 October 1997.
The double-blind study, conducted at St. Mary's Hospital in London, involved 36 healthy female volunteers who administered either PRO 2000 Gel or a placebo gel intravaginally for up to two weeks. No serious adverse events were reported. A detailed analysis of the data is underway.
In June, Procept announced the completion of its first Phase I clinical trial of PRO 2000 Gel at the Institute of Tropical Medicine in Antwerp, Belgium. On October 22, Dr. Lut Van Damme, one of the principal investigators, will present unblinded data from the Antwerp trial at the International Congress of Sexually Transmitted Diseases in Seville, Spain. Results from this study also indicate that PRO 2000 Gel is safe and well tolerated in healthy women.
"The successful completion of the Phase I clinical program allows us to focus on the design and implementation of Phase II safety trials involving sexually active couples," said Stanley C. Erck, president and CEO. "The safety and tolerance data gathered in these studies should enable us to move quickly into Phase II/III trials in collaboration with world health agencies."
Procept Inc. is engaged in the research and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. Procept is developing therapeutics for the treatment of autoimmune diseases, organ transplant rejection and infectious diseases, such as AIDS and tuberculosis. Founded in 1985 and traded on the Nasdaq National Market System under the symbol PRCT, Procept is located in Cambridge, Mass.
--30--mb/bos*
CONTACT: Procept Inc. Stanley C. Erck, 617/491-1100 or INFOCUS Inc. Karen M. Goldman, 609/683-9055
Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
971021
BW971009
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .